Claudia S. Zemmrich
Cloppenburg, NI, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany.
Journal: Frontiers in cardiovascular medicine
Published: September 26, 2023
Leukocyte telomere length and mitochondrial DNA copy number associate with endothelial function in aging-related cardiovascular disease.
Journal: Frontiers in cardiovascular medicine
Published: February 02, 2023
Autophagy-related genes analysis reveals potential biomarkers for prediction of the impaired walking capacity of peripheral arterial disease.
Journal: BMC medicine
Published: January 02, 2023
Effect of ACEI and ARB treatment on nitric oxide-dependent endothelial function.
Journal: VASA. Zeitschrift fur Gefasskrankheiten
Published: August 25, 2021
Risk Factor Management in Non-Metropolitan Patients with Coronary and Peripheral Artery Disease - A Protocol of a Prospective, Multi-Center, Quality Improvement Strategy.
Journal: Vascular health and risk management
Published: February 19, 2021
Preulcerous Risk Situation in Diabetic Foot Syndrome: Proposal for a Simple Ulcer Prevention Score.
Journal: Journal of diabetes science and technology
Published: June 12, 2020
German guideline on the diagnosis and treatment of peripheral artery disease - a comprehensive update 2016.
Journal: VASA. Zeitschrift fur Gefasskrankheiten
Published: January 28, 2017
CMR First-Pass Perfusion for Suspected Inducible Myocardial Ischemia.
Journal: JACC. Cardiovascular imaging
Published: May 31, 2016
The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry.
Journal: Journal of human hypertension
Published: May 16, 2014
Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.
Journal: Clinical drug investigation
Published: April 11, 2014
Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
Journal: Clinical drug investigation
Published: February 01, 2014
Last Updated: 09/26/2026